Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer

Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer - Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038892

Enrollment

100

Registered

2019-12-15

Start date

2019-11-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Aged 20 years or older 2) Histological or cytological proven NSCLC 3) EGFR mutation positive 4) After acquired resistance to 1st/2nd generation EGFR-TKI

Exclusion criteria

Exclusion criteria: 1) patients treated with immunocheckpoint inhibitors after acquired resistance 1st/2nd generation EGFR-TKI 2) patients received at least 1 regimen of anti tumor therapy within 3 months prior to initiation of 1st/2nd generation EGFR-TKI treatment 3) complicated by haemophilia 4) complicated by leukaemia 5) complicated by severe heart failure

Design outcomes

Primary

Measure	Time frame
ICER of EGFR T790M mutant testing	—

Secondary

Measure	Time frame
Time to treatment failure (TTF), Overall survival (OS), Cost	—

Countries

Japan

Contacts

Public ContactTakafumi Hosokawa

Daiichi Sankyo Co., Ltd. Medical Affairs Division

hosokawa.takafumi.bd@daiichisankyo.co.jp03-6225-1111

Outcome results